Sandostatin LAR Depot

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Novartis, Endo Pharmaceuticals

Conditions

AcromegalyDiarrheaNeoplasmsObesityPrimary Insulin Hypersecretion

Phase 2

Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

CompletedNCT00094146

NovartisObesity, Primary Insulin Hypersecretion

Start: 2002-01-31End: 2002-12-31Target: 160Updated: 2009-09-22

Phase 3

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

TerminatedNCT00765323

Endo PharmaceuticalsAcromegaly

Start: 2008-09-30End: 2011-06-30Updated: 2013-09-27

Phase 4

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

CompletedNCT00050635

Novartis PharmaceuticalsDiarrhea, Neoplasms

Start: 2002-12-31End: 2003-07-31Target: 150Updated: 2009-11-19

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

CompletedNCT01789281

Novartis PharmaceuticalsNeoplasms

Start: 2013-05-14End: 2020-08-28Updated: 2021-06-11